| Patient | Irène Joliot-Curie |
|---|---|
| Date of birth | 1897-09-12 |
| Identifiers | MRN HR-RB003-SYN-TD; SSN (made up) 000-03-8841 |
| Document date | 1955-09-16 |
| Author | Solène Marchand-Ellis, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-day review, seen the same morning by hematology for a bone marrow biopsy. [S]
Mrs. Joliot-Curie returns two days after her first visit and was seen this morning by Dr. Engquist-Mensah of hematology/oncology, who performed a bone marrow aspiration and biopsy. She feels more tired than two days ago and is breathless on one flight of stairs. Her gums still ooze when she brushes, and two new bruises have appeared on her thighs. She has had no fever, chills, nosebleeds, blood in the urine or stool, headache, or confusion. She has avoided aspirin as advised. She has written down her history of radiation work and the laboratory accident, and has begun asking her employer's radiation safety office for her dose records. [S]
| Element | Detail |
|---|---|
| Symptoms | More tired; breathless on one flight; gum oozing; new bruises; no fever |
| Weight | 53.8 kg |
| Testing today | Bone marrow aspiration and biopsy with flow cytometry, cytogenetics and molecular panel; blood count; INR and fibrinogen; hepatitis B, hepatitis C and HIV tests; HLA typing; chest X-ray |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever, chills or night sweats |
| Respiratory | Positive | Breathless on one flight of stairs; no cough |
| Ears, nose, mouth, and throat | Positive | Gum oozing; no nosebleeds |
| Integumentary | Positive | New bruises on both thighs |
| Neurological | Negative | No headache, visual change or confusion |
5 systems reviewed. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1955-09-16 | Body height | 163 | cm | S |
| 1955-09-16 | Body weight | 53.8 | kg | S |
| 1955-09-16 | Body mass index (BMI) [Ratio] | 20.2 | kg/m2 | S |
| 1955-09-16 | Systolic blood pressure | 114 | mm[Hg] | S |
| 1955-09-16 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1955-09-16 | Heart rate | 100 | /min | S |
| 1955-09-16 | Respiratory rate | 18 | /min | S |
| 1955-09-16 | Body temperature | 37.3 | Cel | S |
| 1955-09-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1955-09-16 | Leukocytes [#/volume] in Blood by Automated count | 1.9 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1955-09-16 | Neutrophils [#/volume] in Blood by Automated count | 0.5 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 1955-09-16 | Hemoglobin [Mass/volume] in Blood | 7.1 | g/dL | 12-15.5 g/dL | Low | S |
| 1955-09-16 | Platelets [#/volume] in Blood by Automated count | 22 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1955-09-16 | Blasts/Leukocytes in Blood by Manual count | 14 | % | None seen normally | High | S |
| 1955-09-16 | Blasts/cells in Bone marrow | 34 | % | Below 5% normally; 20% or more defines AML | High | S |
| 1955-09-16 | INR in Platelet poor plasma by Coagulation assay | 1.1 | {INR} | 0.8-1.2 | Normal | S |
| 1955-09-16 | Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay | 310 | mg/dL | 200-400 mg/dL | Normal | S |
Vital signs recorded on 1955-09-16; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Pale and tired but alert; weight 53.8 kg; pulse 100 |
| Skin | Several bruises on the thighs and shins; petechiae on the lower legs |
| Mouth | Gum petechiae; no gum swelling |
| Lymph nodes | None enlarged |
| Abdomen | No enlarged liver or spleen |
| Bone marrow site | Right posterior iliac crest dressing dry |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review booked | resolved | confirmed | D61.818 | S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D). |
| Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemia | active | confirmed | C92.00 | S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented. |
| Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years ago | active | confirmed | Z57.1 | S — Synthetic modern coding of her documented occupational exposure. |
| Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active disease | active | confirmed | Z86.11 | S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with differential and smear | At diagnosis; two to three times a week during induction; before each cycle | Completed today | White cells 1.9, neutrophils 0.5, hemoglobin 7.1 g/dL, platelets 22 x10^3/uL, blasts 14% on the smear |
| Laboratory | Bone marrow: morphology, flow cytometry, cytogenetics, molecular panel | At diagnosis; day 21 to 28 of cycle 1; then as response and transplant planning require | Completed today | Aspirate 34% myeloblasts with multilineage dysplasia; flow cytometry myeloid; cytogenetics and molecular panel sent |
| Laboratory | Coagulation tests (INR, fibrinogen) to exclude the coagulopathy of acute promyelocytic leukemia | At diagnosis | Completed today | INR 1.1, fibrinogen 310 mg/dL: no coagulopathy; rapid PML::RARA negative |
| Laboratory | Chemistry: electrolytes, creatinine, calcium, phosphate, uric acid, LDH, liver tests | At diagnosis; during venetoclax ramp-up for tumor lysis; then weekly in cycle 1 and before each cycle | Up to date | Normal kidney and liver tests two days ago; LDH 412 U/L and uric acid 6.4 mg/dL; repeat on the first treatment day |
| Examination | Fitness: performance status, comorbidity (HCT-CI), echocardiogram, lung function | Before choosing induction | Ordered | ECOG 1 two days ago; echocardiogram, ECG and lung function tests booked for the results review |
| Medication safety | Transfusion support: thresholds, irradiated and leukoreduced products | At each blood count | Completed today | Hemoglobin 7.1 g/dL with breathlessness: one unit of irradiated, leukoreduced red cells today; platelets 22 without serious bleeding: no transfusion, as the biopsy is safe at this count |
| Self-management | Infection prophylaxis and the fever plan | From diagnosis | Completed today | Fever plan given in writing: 38.0 °C or more means the emergency department at once; thermometer at home |
| Laboratory | Hepatitis B, hepatitis C and HIV testing before therapy | Once, before therapy | Completed today | Hepatitis B surface antigen, core antibody and surface antibody, hepatitis C antibody and HIV test sent |
| Referral | HLA typing and allogeneic transplant evaluation | At diagnosis for any patient who may be a transplant candidate | Completed today | HLA typing sent |
| Self-management | Occupational exposure history and dose records | At diagnosis | Completed today | History documented; written request for records begun |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022); Khoury JD, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022 (PMID 35732831) (2022); Arber DA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022 (PMID 35767897) (2022); Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023); Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (PMID 32716741) (2020); 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026); 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026)
Follow-up: Review when the cytogenetics and molecular results are back, in about ten days, with the echocardiogram and lung function tests. Blood count twice weekly with transfusion as needed. Emergency department at once for a temperature of 38.0 °C or more or bleeding that does not stop. Next scheduled visit 1955-09-28: genetic results, classification and risk, fitness for treatment, early palliative care, and day 1 of azacitidine with venetoclax. [S]